Amarin drug shows Parkinson’s promise
Published: January 11, 2006 | 3246th good news item since 2003
Drug developer Amarin Corp. said Tuesday that it expects to launch human clinical trials for its Parkinson’s disease treatment candidate later in the year after releasing promising animal study data.
Amarin shares rose 11 cents, or 8.2 percent, to $1.40 in morning trading on the Nasdaq. The stock has dwindled from a 52-week high of $3.45 last January and hit a 52-week low of $1.03 in December.
The company said preclinical studies of Miraxion showed that the treatment increased the activation of tyrosine-specific protein kinase, an enzyme that is critical in increasing dopamine levels in Parkinson’s patients. Parkinson’s disease patients suffer from lowered levels of dopamine, a neurotransmitter chemical that transmits signals between nerve cells.
Miraxion was also shown to enhance learning performance, improve motor function and reduced instances of very slow movement in animal models of Parkinson’s disease.